Publications by authors named "E Martell"
Article Synopsis
- The mitochondrial pyruvate carrier (MPC) plays a key role in connecting glycolysis to mitochondrial metabolism and its function in glioblastoma (GBM) post-treatment is not well understood.
- Through in vitro and in vivo studies, the research shows that the MPC is crucial in regulating metabolism after treatments like temozolomide (TMZ) and radiation, specifically inhibiting differentiation in GBM cells.
- The study highlights the potential for using MPC inhibitors to enhance the effectiveness of current therapies and improve survival rates for GBM patients.
OTX2 is a transcription factor and known driver in medulloblastoma (MB), where it is amplified in a subset of tumours and overexpressed in most cases of group 3 and group 4 MB. Here we demonstrate a noncanonical role for OTX2 in group 3 MB alternative splicing. OTX2 associates with the large assembly of splicing regulators complex through protein-protein interactions and regulates a stem cell splicing program.
View Article and Find Full Text PDFArticle Synopsis
- CAR-T therapy has shown promising results in treating relapsed/refractory multiple myeloma (RRMM), but frequent relapses highlight a need to understand mechanisms of resistance.
- Researchers used advanced flow cytometry to analyze T cell changes in patients at various stages of multiple myeloma, finding distinct T cell phenotypes in RRMM and post-CAR-T relapse cases compared to healthy individuals.
- In RRMM and post-CAR-T relapse patients, T cells exhibited multiple inhibitory markers, suggesting that these markers may play a significant role in the resistance observed after CAR-T therapy.
Despite tremendous research efforts, successful targeting of aberrant tumor metabolism in clinical practice has remained elusive. Tumor heterogeneity and plasticity may play a role in the clinical failure of metabolism-targeting interventions for treating cancer patients. Moreover, compensatory growth-related processes and adaptive responses exhibited by heterogeneous tumor subpopulations to metabolic inhibitors are poorly understood.
View Article and Find Full Text PDF